Thank you, Jonathan.
across by We are encouraged all momentum of our business. areas strong
on On the are we commercialization front, for year. launch this track
the and us feedback as same that support from only in our also for generate platinum we given have of customer test to high-quality access performance been simple sites laboratories own robust projects. research but voice new Working demonstration with they invaluable conduct We and beginning release workflows. own and data hardware and partners to early continue their upgrades to ability our move sequencing gathering to the reproducing develop instrument, not the has this improved to of protocols
proteomics life development. Our external technology areas industry and demonstrate research, commercialization aspects science drug to team exciting of of on numerous of our collaborators diagnostics with engaging power all applications and is partners impacting actively in the
marketing of to our demonstrating of the Quantum-Si’s note interrogate an XX,XXX ability shared encoding development modifications, genes there we important in second application the human of of activities, background, is technology protein part way our By As which post-translational function. protein genome. are indicator
we time proteome not by or domain are the contrast, a proteins sequencing PTMs, method to coded can enabled including variants, They X which detected and semiconductor in have or look changes over in Aptamer scalable While at and undergo million genes. the genome protein scope the arrays coded the cannot or resulting specific resolution, different level as acid RNA. proprietary protein proteoforms, by subset increases only understand variants post-translational of modifications our presence affinity-based of not are the protein measuring human modifications, the amino for a regions. the convenience In at detect million proteins to they confirm in modifications that Quantum-Si’s post-translational
a Quantum-Si This be transform builds and paper, other we to untapped researchers foundational hard to study a bringing again, the size from helping with Quantum-Si’s drug recently that this, technology switches of website. represent develop this potential. variants proteoforms. our can along make protein page whether disease difficult notes the method work. the the world frontier. It of released new understand note is is can where tech unlock not use a a can future our new that in Once how key disease company analog role or us Given up application that unique biomarkers play application is digital proteins of novel resource can on/off help critical going and therapies these and found on detect a to white molecular on or in these progression the to someone the which Protein variants technology and tell can
protein next sequencing. the excited detection demonstrate notes to continue protein in application by the months. power time platinum over additional the the sequencing provides The powered platinum are few domain advantages sequencing includes over through of field molecule of We platform proteomics, competitors to that single
investment access and ultimate complement allow sizes, to built human or for full legacy to is lab technologies that platform ease-of-use as a proteome can all labs, Our low interrogate solution. a existing proteomics upfront workflows the end-to-end supplant with
development ramp to addition, our up refine In activities. we business continue and
Pennsylvania is operations our roadmap several initial million well and contract instruments take launch later through our Human with this up supply initiatives a our and front, law Moore’s chip facility, Human continue our power up the World behind for to the of advance Society American Congress. support our industry to platinum year, Organization launch Neuroscience, targeting On are capacity and while conferences we We we executing are our scale inventory place the packaging chain of at X commercial this with chip manufacturer, Garnet including continue it. of Proteome underway build year, semiconductor product on Valley, Society to the Genetics, wells, for assembly on will an
review we with turn our finished continue like to work and results. financial our over our Lastly, closely to vendors scale reagent now to kit Claudia the to call I’d up to supply.
